China-based Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialisation of innovative medicines and vaccines, has announced that Dr Mike Berry has been appointed Chief Technology Officer. He has more than 30 years of industrial experience in advancing projects from pre-clinical development phase to commercial stage.

Dr Berry brings extensive experience in development, scale-up and manufacturing of biopharmaceuticals, including strong knowledge of international regulatory guidelines for Good Manufacturing Practices (GMP) and Chemistry, Manufacturing and Control (CMC).

As the Chief Technology Officer, Dr Berry will be responsible for all CMC activities at Everest while being in charge of the operations and management of the Company's manufacturing facility in Jiashan, Zhejiang. This is an advanced facility built to meet global and Chinese GMP standards with an annual production capacity of 700 million doses of mRNA vaccines.

Prior to this appointment, Dr Berry was most recently Chief Technical Operations Officer for global operations at Clover Biopharmaceuticals, responsible for Clover's global drug substance and drug product development and manufacturing. Before that, Dr Berry held leadership positions at multiple US and international biotech firms including Dynavax Technologies Corp., and Novartis Diagnostics and also was a CMC consultant at BioTechLogic, Inc.  He has extensive experience in large and small molecule drug substance and drug product development, manufacturing and testing as well as drug product supply chain management.